Korea FDA Rebuts Reports Of Compulsory Licensing For Roche's Tamiflu
This article was originally published in PharmAsia News
Executive SummarySEOUL - Korea FDA rejected Friday local press reports that the Korean government - jittery over the rising number of local people infected with A/H1N1- will soon exercise the option of "compulsory licensing" to produce generic versions of Roche's Tamiflu (oseltamivir)
You may also be interested in...
Beyond its main focus of biosimilars, Celltrion is pursuing an influenza therapy that would be its first original product.
The president of the National Health Insurance Service told lawmakers his agency is assessing the feasibility of a state-owned pharma, which the domestic industry group said could put a pinch on reimbursement negotiations.